Related content

Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients

By Miura Masatomo   Satoh Shigeru   Kagaya Hideaki   Saito Mitsuru   Numakura Kazuyuki   Tsuchiya Norihiko   Habuchi Tomonori  

Pharmacogenomics, Vol. 12, Iss. 7, 2011-07 ,pp. : 977-984

Future Medicine

Access to resources Recommend Favorite

Influence of Cytochrome P450 3A5 (CYP3A5) Genetic Polymorphism on the Pharmacokinetics of the Prolonged-Release, Once-Daily Formulation of Tacrolimus in Stable Renal Transplant Recipients

By Glowacki François   Lionet Arnaud  

Clinical Pharmacokinetics, Vol. 50, Iss. 7, 2011-07 ,pp. : 451-459

Adis International

Access to resources Recommend Favorite

Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients

By Miura Masatomo  

Clinical Drug Investigation, Vol. 27, Iss. 4, 2007-01 ,pp. : 251-258

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

By Eap Chin   Buclin Thierry   Hustert Elisabeth   Bleiber Gabriela   Golay Kerry   Aubert Anne-Catherine   Baumann Pierre   Telenti Amalio   Kerb Reinhold  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 4, 2004-06 ,pp. : 231-236

Springer Publishing Company

Access to resources Recommend Favorite

The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients

By de Jonge Hylke   Metalidis Christoph   Naesens Maarten   Lambrechts Diether   Kuypers Dirk RJ  

Pharmacogenomics, Vol. 12, Iss. 9, 2011-09 ,pp. : 1281-1291

Future Medicine

Access to resources Recommend Favorite